GlassScriptPhysician profile
Taylor Lavender
NPI 1356826986
$7,439.32
in general payments reported to CMS, 2019-2025
59 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,350 · 2022: $3,375 · 2023: $1,389 · 2024: $125 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.41 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $512.17 | 2021-2025 | Jakafi, Niktimvo, Pemazyre |
| Novartis Pharmaceuticals Corporation | $448.78 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $434.58 | 2021-2023 | Keytruda, Lynparza, Reblozyl |
| Taiho Oncology, INC. | $419.65 | 2021-2023 | |
| Abbvie INC. | $395.29 | 2021-2025 | |
| Astellas Pharma US INC | $374.06 | 2021-2023 | Padcev |
| Janssen Biotech, INC. | $304.58 | 2021-2025 | Imbruvica, Darzalex, Rybrevant |
| Seagen INC. | $292.60 | 2021-2023 | Tukysa, Adcetris |
| Astrazeneca Pharmaceuticals LP | $271.54 | 2021-2022 | |
| Daiichi Sankyo INC. | $260.73 | 2021-2023 | Enhertu, Injectafer |
| Amgen INC. | $249.28 | 2021-2023 | Kyprolis, Nplate, Vectibix |
| Pfizer INC. | $237.70 | 2021-2023 | |
| Exelixis INC. | $207.39 | 2021-2023 | Cabometyx |
| Kite Pharma, INC. | $193.00 | 2021-2023 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $182.09 | 2021-2023 | Alunbrig |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Lavender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.